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Edited by Richard MaraisAbstract The multisite phosphorylation of the transcription
factor ATF-2 was investigated using transformed embryonic
ﬁbroblasts from wild-type mice and mice deﬁcient in c-Jun N-
terminal kinases (JNK)1 and 2, and in the presence and absence
of inhibitors of p38 mitogen-activated protein kinase (p38
MAPK) and the classical MAP kinase cascade. In wild-type
cells, p38 MAPK and extracellular signal-regulated protein
kinase (ERK)1/2 were not rate limiting for the phosphorylation
of Thr69, Thr71 or Ser90. In JNK-deﬁcient cells, p38 MAPK
substituted for JNK partially in the phosphorylation of Thr69
and p38 MAPK or ERK1/2 in the phosphorylation of Thr71.
JNK was the only MAP kinase that phosphorylated Ser90 under
the conditions examined.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Epidermal growth factor1. Introduction
Activating transcription factor-2 (ATF-2) [1] is a ubiqui-
tously expressed member of the ATF/cyclic AMP-response
element (CRE)-binding protein family of basic region-leucine
zipper (bZIP) transcription factors. Upon activation, ATF-2
forms homodimers or heterodimers with other transcription
factors of the ATF or activating protein-1 (AP-1) families
[2–5], which then target gene promoters via the CRE or AP-1
binding sites.
In unstimulated cells, ATF-2 is maintained in an inhibited
form by an intramolecular interaction between its activation
and bZIP domains [6]. A transcriptional response can be in-* Corresponding author. Fax: +44-1382-223778.
E-mail address: p.cohen@dundee.ac.uk (P. Cohen).
Abbreviations: AP-1, activating protein 1; ATF-2, activating transcrip-
tion factor-2; CRE, cyclic AMP-response element; E1A, early adeno-
virus protein 1A; EGF, epidermal growth factor; ERK, extracellular
signal-regulated protein kinase; GST, glutathione S-transferase; HAT,
histone acetyl transferase; JNK, c-Jun N-terminal kinase; MAPK,
mitogen-activated protein kinase; MAPKAP-K2, MAPK-activated
protein kinase 2; PMA, phorbol-12-myristate 13-acetate; Rb, retino-
blastoma protein; TNF, tumour necrosis factor; bZIP, basic region-
leucine zipper
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retinoblastoma (Rb) tumour suppressor protein [7] and the
early adenovirus 1A (E1A) protein [8–12], or by the phos-
phorylation of residues within its N-terminal transcriptional
activation domain.
The phosphorylation of ATF-2 in vitro by a p54 MAP ki-
nase (subsequently identiﬁed as an isoform of c-Jun N-termi-
nal kinase (JNK)) and p42 MAP kinase (usually called
extracellular-signal regulated protein kinase 2 (ERK2)) was
ﬁrst reported to increase its DNA-binding activity 12 years ago
[13]. Subsequently, JNK was found to become activated in
response to ultraviolet (UV) radiation, pro-inﬂammatory cy-
tokines and genotoxic agents, while UV-radiation was shown
to induce the phosphorylation of ATF-2 [14–16], suggesting
that JNK might mediate the phosphorylation and activation of
ATF-2 in vivo. Phosphopeptide mapping and mutational
analysis revealed that the UV-induced phosphorylation of
ATF-2 in cells occurred at Thr69, Thr71 and Ser90. The
phosphorylation of Thr69 and Thr71 was found to be neces-
sary for the transcriptional activation of ATF-2 in response to
UV and genotoxic agents, because activation did not occur if
either or both of these two sites were mutated to Ala [14–16].
In contrast, the mutation of Ser90 to Ala had little eﬀect on
transcriptional activity [15,16]. The phosphorylation of Thr69
and Thr71 was also required for E1A- and Rb-stimulated gene
expression [14,15] and for the intrinsic histone acetyltransfer-
ase (HAT) activity of ATF-2 [17], but Ser90 phosphorylation
was not required for the response to E1A [15] or HAT activity
[17].
The importance of JNK in mediating the phosphorylation of
ATF-2 was subsequently established in a number of ways, but
most notably by the generation of mice that do not express
JNK1 or JNK2, in which the tumour necrosis factor (TNF)a-
induced phosphorylation of ATF-2 at Thr71 was greatly re-
duced [18]. However, another group reported that, in response
to diﬀerent stimuli, the phosphorylation of ATF-2 at Thr69 and
Thr71 was reduced, but not abolished in JNK-deﬁcient cells,
indicating that other protein kinases are capable of phosphor-
ylating these sites, if JNK isoforms are not expressed [19].
In this paper, we have generated a phospho-speciﬁc anti-
body that recognises ATF-2 phosphorylated at Ser90 and used
this and other commercially available phospho-speciﬁc anti-
bodies that recognise ATF-2 phosphorylated at Thr69 and
Thr71 to analyse the phosphorylation of all three sites in
response to a variety of agonists in transformed embryonicblished by Elsevier B.V. All rights reserved.
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not express either JNK1 or JNK2.2. Materials and methods
2.1. Materials
The sources of all reagents, other than those detailed below, are
given elsewhere [20].
2.2. Cloning and expression of ATF-2
Full length ATF-2 was cloned and inserted into a pGEX vector.
Glutathione-S-transferase (GST)-ATF-2 was then expressed in Esch-
erichia coli BL21, puriﬁed by aﬃnity chromatography on glutathione–
Sepharose and used for antibody production and as a substrate for
diﬀerent MAP kinase family members.
2.3. Protein kinases and their assay
JNK1a1, p38a mitogen-activated protein kinase (MAPK), p38b
MAPK and ERK2 were expressed, puriﬁed, activated and assayed as
described previously [21].
2.4. Antibodies
An antibody capable of immunoprecipitating ATF-2 (anti-ATF-2)
was raised in a sheep against GST-ATF-2 and the antisera aﬃnity
puriﬁed on CH-Sepharose to which GST-ATF-2 had been coupled
covalently, then passed through GST-Sepharose to remove the anti-
GST antibodies. The phosphopeptide FNELApSPFENE (where pS is
phosphoserine), corresponding to residues 85–95 of human ATF-2,
was coupled separately to bovine serum albumin and keyhole limpet
haemocyanin before being mixed and injected into a sheep. The anti-
sera were aﬃnity puriﬁed on CH-Sepharose to which the phosphory-
lated peptide had been coupled covalently. These anti-pSer90
antibodies were used for immunoblotting in the presence of the un-
phosphorylated form of the peptide antigen (10 lg/ml) to neutralise
any antibodies that recognised unphosphorylated ATF-2. Antibodies
that recognise ATF-2 phosphorylated at Thr71 (anti-pThr71), or both
Thr69 and Thr71 (anti-pThr69/pThr71) were purchased from Cell
Signalling Technologies (Hitchin, UK). The sources of other anti-
bodies are given elsewhere [20].Fig. 1. Characterisation of phospho-speciﬁc antibodies that recognise ATF-2
was left unphosphorylated (no kinase, NK) or maximally phosphorylated w
Immunoblotting was then carried out using the phospho-speciﬁc antibodie
unphosphorylated ATF-2 equally well (ATF-2), in the presence or absence (n
FNELASPFENE (Ser90); FNELApSPFENE (pSer90); VADQpTPTP
QpTPpTPTRFLK (pThr69/pThr71). The preﬁx ‘‘p’’ denotes the phosphory2.5. Cell culture and stimulation
Wild-type and JNK)/) ﬁbroblasts were cultured, lysed, exposed to
pharmacological inhibitors and stimulated with agonists as described
elsewhere [20]. Further details are given in the ﬁgure legends.
2.6. Immunoprecipitation and immunoblotting of ATF-2
ATF-2 was immunoprecipitated from 2 mg cell lysate protein with
anti-ATF-2 and then immunoblotted with the phosphospeciﬁc anti-
bodies that recognise ATF-2 at particular sites. The exact procedure is
as detailed previously for anti-c-Jun and the phospho-speciﬁc anti-
bodies that recognise this protein [20].3. Results
3.1. Characterisation of anti-ATF-2 antibodies
The antibodies required to analyse the in vivo phosphoryla-
tion state of ATF-2 were ﬁrst characterised in vitro. The speci-
ﬁcity of the antibody that recognises ATF-2 phosphorylated at
Ser90 was veriﬁed by the demonstration that recognition was
prevented by preincubation with the phosphopeptide immuno-
gen, but not by incubationwith phosphopeptides corresponding
to the sequences surrounding the other N-terminal phosphory-
lation sites (Fig. 1). The speciﬁcity of this antibody was also
veriﬁed by the demonstration that when preincubated with
the unphosphorylated form of the peptide immunogen, it only
recognised ATF-2 after phosphorylation by JNK. In contrast,
the antibody raised against the ATF-2 protein recognised
phosphorylated and unphosphorylated ATF-2 equally well
(Fig. 1).
The speciﬁcities of the commercially available antibodies
that recognise ATF-2 when phosphorylated at both Thr69 and
Thr71, or only phosphorylated at Thr71, were veriﬁed in
analogous experiments to those described above for the anti-
pSer90 antibody (Fig. 1). The antibody recognising ATF-2
phosphorylated at both Thr69 and Thr71 was not neutralised
by either of the two singly phosphorylated peptides alonephosphorylated at Thr69, Thr71 or Ser90. Bacterially expressed ATF-2
ith JNK and 100 ng aliquots spotted onto a nitrocellulose membrane.
s indicated or with an antibody that recognises phosphorylated and
one) of the competitor peptides shown. The competitor peptides were:
TRFLK (pThr69); VADQTPpTPTRFLK (pThr71); and VAD-
lated residue.
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tralised by the doubly phosphorylated peptide (Fig. 1).
Therefore, this antibody recognises ATF-2 only when phos-
phorylated at both Thr69 and Thr71. The antibody that rec-
ognises ATF-2 only when phosphorylated at Thr71 was
unaﬀected by the peptide phosphorylated at Thr69, but neu-
tralised by the peptide phosphorylated at Thr71 or the peptide
phosphorylated at both Thr69 and Thr71 (Fig. 1). Therefore,
this antibody recognises ATF-2 phosphorylated at Thr71,
whether or not Thr69 is phosphorylated.Fig. 2. Site-speciﬁc phosphorylation of ATF-2 in vitro by diﬀerent
MAP kinases. Bacterially expressed ATF-2 was left unphosphorylated
(no kinase, NK) or phosphorylated for 30 min at 30 C with 1 U/ml of
JNK1a1, ERK2, p38aMAPK or p38bMAPK. Aliquots (100 ng) were
spotted onto a nitrocellulose membrane and immunoblotted with the
phospho-speciﬁc antibodies indicated or with an antibody that rec-
ognizes phosphorylated and unphosphorylated ATF-2 equally well
(ATF-2). The preﬁx ‘‘p’’ denotes the phosphorylated residue.3.2. Site-speciﬁc phosphorylation of ATF-2 in vitro by MAP
kinase family members
MAP kinase family members normally phosphorylate serine
and threonine residues that are followed by proline, and
Thr69, Thr71 and Ser90 all lie in such motifs. In order to assess
which sites could be phosphorylated by diﬀerent MAP kinase
family members in vitro, we incubated ATF-2 with MgATP in
the presence of relatively high concentrations of these protein
kinases and examined the phosphorylation of each site using
the phospho-speciﬁc antibodies characterised above. These
experiments showed that JNK1a1 phosphorylated all three
sites, while ERK2 was only able to phosphorylate Thr71
(Fig. 2). As reported previously [22], p38a and p38b MAP
kinases phosphorylated Thr69 and Thr71, but not Ser90.Fig. 3. Phosphorylation of three sites in ATF-2 in embryonic ﬁbroblasts from wild-type (WT) and JNK)/)mice. Cells were stimulated (A) for 30 min
with anisomycin (10 lg/ml), (B) for 15 min with TNFa (10 ng/ml), (C) for 15 min with EGF (100 ng/ml) and (D) for 30 min with PMA (100 ng/ml),
and lysed. ATF-2 was immunoprecipitated from the lysates, denatured in SDS, subjected to SDS–PAGE and transferred to nitrocellulose membrane.
The membranes were immunoblotted with antibodies that recognise ATF-2 phosphorylated at Thr69/Thr71, Thr71 and Ser90, as well as with an
antibody that recognises the phosphorylated and unphosphorylated forms of ATF-2 equally well. Similar results were obtained in another inde-
pendent experiment. The preﬁx ‘‘p’’ denotes the phosphorylated residue.
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embryonic ﬁbroblasts in response to anisomycin, TNFa,
epidermal growth factor and phorbol-12-myristate
13-acetate
Transformed ﬁbroblasts from wild-type and JNK)/) cells
(that do not express JNK1 or JNK2) express similar levels of
ATF-2 (Fig. 3) and were used to analyse the phosphorylation
of ATF-2 in response to a variety of stimuli. The JNK3 iso-
form is not expressed in these cells. The protein synthesis in-
hibitor anisomycin (Fig. 3A) and TNFa (Fig. 3B) induced the
phosphorylation of ATF-2 at Thr69, Thr71 and Ser90 in wild-
type ﬁbroblasts, but no phosphorylation of Ser90 occurred in
the JNK)/) ﬁbroblasts. In contrast, the phosphorylation of
ATF-2 at Thr69 and Thr71 in the JNK)/) ﬁbroblasts was
reduced, but not abolished. Epidermal growth factor (EGF)
also induced the phosphorylation of ATF-2 at Thr69 and
Thr71 in wild-type ﬁbroblasts, but no EGF-induced phos-
phorylation of Ser90 was detected in either these or JNK)/)
ﬁbroblasts (Fig. 3C). As for TNFa-induced phosphorylation,
the EGF-induced phosphorylation of Thr69 and Thr71 was
reduced, but not abolished in the JNK)/) ﬁbroblasts
(Fig. 3C). The tumour-promoter phorbol-12-myristate 13-ac-
etate (PMA) induced phosphorylation of Thr71 in wild-type
ﬁbroblasts, which was reduced but not abolished in JNK)/)
ﬁbroblasts, but this agonist did not increase Thr69 or Ser
phosphorylation in wild-type or JNK)/) ﬁbroblasts (Fig. 3D).Fig. 4. Eﬀect of protein kinase inhibitors on the anisomycin- and PMA-ind
JNK)/) ﬁbroblasts. Wild-type (WT) (A, B) and JNK)/) (C, D) cells were in
184352, stimulated for 30 min with or without anisomycin (10 lg/ml) or PM
antibodies that recognise ATF-2 phosphorylated at Thr69/Thr71 or Thr71
unphosphorylated forms of ATF-2 equally well (see legend to Fig. 3). Furth
precipitation) using antibodies that recognise MAPKAP-K2 phosphorylate
phorylated JNK (A, B) and an antibody that recognises the phosphorylated a
were obtained in another independent experiment. The preﬁx ‘‘p’’ denotes thThe phosphorylation of ATF-2 induced by anisomycin,
TNFa and EGF, but not by PMA, was accompanied by a de-
crease in the mobility of this protein. Taken together, these
observations suggest that the decrease in mobility of ATF-2
results from the combined phosphorylation of Thr69 andThr71.
3.4. Eﬀects of protein kinase inhibitors on the anisomycin and
PMA-induced phosphorylation of ATF-2
In ﬁbroblasts, anisomycin is a potent activator of JNK and
p38 MAPK, but a much weaker activator of ERK1/ERK2.
Conversely, PMA is a potent activator of ERK1/ERK2 and
weak activator of JNK and p38 MAPK. We therefore, studied
the site-speciﬁc phosphorylation of ATF-2 in the presence and
absence of SB 203580 (a potent and relatively speciﬁc inhibitor
of p38 MAPK) [23] and/or PD 184352 (a potent and speciﬁc
inhibitor of MAPK kinase 1, the enzyme that activates ERK1
and ERK2) [24]. These experiments revealed that, in wild-type
cells, SB 203580 did not aﬀect the anisomycin-induced phos-
phorylation of Thr69 and Thr71 (Fig. 4A), while PD 184352
did not aﬀect the PMA-induced phosphorylation of Thr71
(Fig. 4B). In contrast, SB 203580 abolished the anisomycin-
induced phosphorylation of Thr69 and Thr71 (Fig. 4C), while
PD 184352 abolished the PMA-induced phosphorylation
(Fig. 4D) of Thr71 in the JNK)/) cells. The phosphorylation
of MAPK-activated protein kinase-2 (MAPKAP-K2), an es-
tablished downstream substrate of p38a, was prevented by SBuced phosphorylation of ATF-2 at Thr69 and Thr71 in wild-type and
cubated for 1 h with (+) or without ()) 10 lM SB 203580 or 2lM PD
A (100 ng/ml) and lysed. Immunoblotting was then performed with
alone, and with an antibody that recognises the phosphorylated and
er aliquots of the cell lysates were immunoblotted (without immuno-
d at Thr334 (A, C), phosphorylated ERK1 and ERK2 (B, D), phos-
nd unphosphorylated forms of JNK equally well (A, B). Similar results
e phosphorylated residue.
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184352, as expected (Fig. 4).
3.5. Eﬀects of protein kinase inhibitors on the TNFa and
EGF-induced phosphorylation of ATF-2
We also studied the site-speciﬁc phosphorylation of ATF-2
after stimulating the ﬁbroblasts with TNFa and EGF, two
agonists that activate both p38 MAPK and the classicalFig. 5. Eﬀect of SB 203580 and PD 184352 on the TNFa-induced phospho
broblasts. Wild-type (WT) (A, B) and JNK)/) (C, D) cells were incubated fo
stimulated for 15 min with TNFa (10 ng/ml) and lysed. ATF-2 was imm
Thr69/Thr71 or Thr71 alone, as well as with an antibody that recognises the p
described in the legend to Fig. 3. Further aliquots of the cell lysates were immu
K2 phosphorylated at Thr334 (A–D), the active phosphorylated forms of JN
ERK1 and ERK2 (B, D). Similar results were obtained in a separate in
residue.
Fig. 6. Eﬀect of PD 184352 and SB 203580 on the EGF-induced phosphory
MEFs. Wild-type (WT) (A) and JNK-deﬁcient (JNK)/)) (B) cells were incub
203580 and then stimulated for 15 min with EGF (100 ng/ml). ATF-2 was im
Thr69/Thr71 or Thr71 alone, as well as with an antibody that recognises the p
described in the legend to Fig. 3. Similar results were obtained in a separate
residue.MAPK cascade in ﬁbroblasts. As found with anisomycin or
PMA, SB 203580 and/or PD 184352 did not aﬀect the TNFa-
induced (Fig. 5A and B) or EGF-induced (Fig. 6A) phos-
phorylation of Thr69 and Thr71 in wild-type cells. In contrast,
SB 203580 abolished the TNFa- (Fig. 5C) or EGF-induced
(Fig. 6B) phosphorylation of Thr69, but the combined addi-
tion of SB 203580 and PD 184352 was needed to abolish the
phosphorylation of Thr71 by these agonists.rylation of ATF-2 at Thr69 and Thr71 in wild-type and JNK)/) ﬁ-
r 1 h with (+) or without ()) 10 lM SB 203580 and/or PD 184352, then
unoblotted with antibodies that recognise ATF-2 phosphorylated at
hosphorylated and unphosphorylated forms of ATF-2 equally well, as
noblotted with antibodies that recognise the active form of MAPKAP-
K (A), and an antibody that recognises the phosphorylated forms of
dependent experiment. The preﬁx ‘‘p’’ denotes the phosphorylated
lation of ATF-2 at Thr69/Thr71 and Thr71 in wild-type and JNK)/)
ated for 1 h with (+) or without ()) 2 lM PD 184352 and/or 10 lM SB
munoblotted with antibodies that recognise ATF-2 phosphorylated at
hosphorylated and unphosphorylated forms of ATF-2 equally well, as
independent experiment. The preﬁx ‘‘p’’ denotes the phosphorylated
Wild-type cells
ANI/TNFα
JNK1/2
ATF-2
EGF
JNK1/2
ATF-2
PMA
JNK1/2
ATF-2 pT71
pT69
pT71
pT69
pT71
pS90
JNK-/-cells
ANI
p38α/ β
TNFα/EGF
p38α /β
PMATNFα/EGF
p38α/β ERK1/2 ERK1/2
PD
SB SB SB
PD
ATF-2 ATF-2 ATF-2 pT71pT71pT69ATF-2
pT69
pT71
A
B
Fig. 7. Summary of the results obtained in this study. (A) Wild-type cells: p38a=b or ERK1/ERK2 are not rate limiting for the phosphorylation of
ATF-2 at Thr69, Thr71 or Ser90. Anisomycin (ANI) or TNFa stimulates the phosphorylation of ATF-2 all three sites, EGF at Thr69 and Thr71 and
TPA at Thr71 only. (B) JNK)/) cells: p38a=b are rate limiting for ANI, TNFa and EGF-induced phosphorylation of Thr69, and ANI–induced
phosphorylation of Thr71. p38a=b or ERK1/ERK2 are both required for maximal phosphorylation of ATF-2 at Thr71 in response to TNFa or
EGF. The TPA-induced phosphorylation of ATF-2 at Thr71 is mediated by ERK1/ERK2. Abbreviations: SB, SB 203580; PD, PD 184352.
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In this paper, we have analysed the multisite phosphoryla-
tion of ATF-2 in wild-type and JNK)/) cells and in the
presence or absence of inhibitors of p38a=b MAPKs (SB
203580) and the classical MAPK cascade (PD 184352) and the
results are summarised in Fig. 7. Although the phosphoryla-
tion of ATF-2 at Ser90 in response to UV radiation has been
reported previously, the present study is the ﬁrst to demon-
strate that JNK isoforms are required for the phosphorylation
of this site in anisomycin or TNFa-stimulated cells, since no
phosphorylation of this residue was detected in JNK)/) cells
(Fig. 3). However, it cannot yet be excluded that JNK does not
phosphorylate Ser90 directly, and that phosphorylation in cells
is catalysed by another proline-directed Ser90 kinase(s) whose
synthesis and/or activation is dependent on JNK expression. In
order to resolve this issue, a potent and selective small mole-
cule inhibitor capable of suppressing JNK activity within
minutes will be needed. However, compounds with the requi-
site potency and speciﬁcity have not yet been described (see
[25]). Consistent with our ﬁnding that JNK, but not ERK2 (or
p38a=b MAPK), phosphorylates Ser90 in vitro (Fig. 2), EGF
or PMA, which are potent activators of the classical MAP
kinase cascade, did not induce the phosphorylation of Ser90 in
ﬁbroblasts.
In contrast to the phosphorylation of Ser90, the phosphor-
ylation of ATF-2 at both Thr69 and Thr71 was reduced in
JNK)/) cells, but not abolished. The residual phosphorylation
of Thr69 plus Thr71 in anisomycin-stimulated JNK)/) cells
was prevented by SB 203580, while the residual phosphoryla-
tion of Thr71 in PMA-stimulated cells was suppressed by PD
184352. Incubation with SB 203580 was suﬃcient to preventthe phosphorylation of Thr69 plus Thr71 in TNFa – or EGF-
stimulated cells, but the combined addition of SB 203580 and
PD 184352 was required to abolish the phosphorylation of
Thr71 by these agonists. These observations indicate that
p38a/p38b MAPKs, but not ERK1/ERK2, can replace JNK
isoforms in the phosphorylation of Thr69, and that both p38a/
p38b MAPKs and ERK1/ERK2 can partially replace JNK
isoforms in the phosphorylation of Thr71 if JNKs are not
expressed (Fig. 7B). These ﬁndings are consistent with our
observation that p38a=bMAPK can phosphorylate Thr69 and
Thr71, while ERK2 can only phosphorylate Thr71 in vitro
(Fig. 2).
The eﬀects of inhibitors on the phosphorylation of Thr69
and Thr71 described in this paper are also consistent with
those reported by another laboratory who stimulated trans-
formed ﬁbroblasts from JNK)/) cells with agonists that were
mostly distinct from those used in the present study [19]. These
investigators reported that the phosphorylation of Thr69 plus
Thr71, or Thr71 alone, induced by UV-C radiation or the
DNA alkylating agent methylmethane sulfonate, was abol-
ished by SB 203580 in the JNK)/) cells, similar to our results
in anisomycin-stimulated JNK)/) cells. They also found that
SB 203580 or U0126 (another inhibitor of the classical MAPK
cascade [26]) were both required to suppress the phosphory-
lation of Thr71 induced by insulin or EGF, similar to our
results with TNFa or EGF.
In the transformed ﬁbroblasts from wild-type mice, SB
203580 and/or PD 184352 had no eﬀect on the phosphory-
lation of ATF-2 by any agonist tested, indicating that nei-
ther p38a /p38b MAPKs nor ERK1/ERK2 are rate limiting
for the phosphorylation of this transcription factor under
the conditions that we have studied (Fig. 7A). The lack of
S. Morton et al. / FEBS Letters 572 (2004) 177–183 183eﬀect of these inhibitors could either mean that JNK activity
alone is suﬃcient for maximal phosphorylation of ATF-2 or
that the binding of JNK to ATF-2 prevents phosphorylation
by p38a/p38b and ERK1/ERK2. The development of a
potent and speciﬁc pharmacological inhibitor of JNK would
help to distinguish between these possibilities. However, in
A14 ﬁbroblasts, in which PMA does not activate JNK or
p38 MAPK, the PMA-induced phosphorylation of ATF-2 at
Thr71 was blocked by U0126, suggesting that ERK1/ERK2
may phosphorylate ATF-2 in at least one JNK-expressing
cell [19].
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